Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Ebullient Evolution

Thu, 29th Oct 2009 08:23
Investment management firm Evolution Group expects to beat full year profit forecasts this year on the back of strong trading across all of its divisions.Revenues from the Investment Banking arm in the second half of 2009 will be at least double those seen in the first half, reflecting the increased corporate activity.The company is responding to this increased activity by boosting the division's headcount by around 10% in the second half of the year.On the Private Client Investment Management side, profits continue to pile up, while funds under management hit a record level of £5bn at the end of September, up from £4.2bn at the end of June. Net fund inflows exceeded £100m in the third quarter.'Given the successful results to date from investments made over the last 12 months and our growing business pipeline, the group is highly confident that it can continue the momentum in profit growth into 2010 and beyond,' the company said.

Related News

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well
25 Apr 2024

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests
4 Apr 2024

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat
19 Mar 2024

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...

EVG.L News

Evgen Pharma Gets European Patent For Sulforaphane Stablising Method
2 May 2018

Evgen Pharma Gets European Patent For Sulforaphane Stablising Method

LONDON (Alliance News) - Drug development company Evgen Pharma said Wednesday that it has secured a European patent recognising its intellectual prope...

Evgen Pharma Begins Research Partnership With Imperial College London
20 Mar 2018

Evgen Pharma Begins Research Partnership With Imperial College London

LONDON (Alliance News) - Drug development company Evgen Pharma PLC has started a new research collaboration with Imperial College London focusing on S...

Evgen Pharma signs service agreement with drug development corsortium
13 Feb 2017

Evgen Pharma signs service agreement with drug development corsortium

(ShareCast News) - AIM-listed Evgen Pharma has signed a services agreement with a consortium of Cheshire-based drug developments firms for its sulfora...

Richard Moulson to join Evgen Pharma as CFO
17 Jan 2017

Richard Moulson to join Evgen Pharma as CFO

(ShareCast News) - Clinical-stage drug development company Evgen Pharma announced the appointment of experienced healthcare executive Richard Moulson ...

Evgen Pharma receives go ahead for haemorrhage drug trial
11 Jan 2017

Evgen Pharma receives go ahead for haemorrhage drug trial

(ShareCast News) - Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has receive...

Evgen Pharma receives approval for breast cancer study
17 Aug 2016

Evgen Pharma receives approval for breast cancer study

(ShareCast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that it has received a Clinical Trial Approval from the...